Home › Companies › Compass Therapeutics, Inc. › 2025-2026

Compass Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Compass Therapeutics, Inc.’s Form 8-K, filed 2026-06-11 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Reported items
165Asset managers
1,088Fund votes
2026-06-10Meeting date

Proxy season: 2025-2026

Explore Compass Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Compass Therapeutics, Inc.

These tallies are Compass Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-11 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Compass Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-10
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Thomas J. Schuetz, M.D., Ph.D.	102,984,184	--	--	18,837,499	21,320,318	Majority: yes
Elect Director: Richard S. Lindahl, M.B.A.	103,453,540	--	--	18,368,143	21,320,318	Majority: yes
Proposal 2: . Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026, by t	137,896,097	181,037	--	5,064,867	--	Majority: yes
Proposal 3: . Non-binding, Advisory Vote on the Compensation of our Named Executive Officers. The stockholders voted to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers, by the votes set forth in the table b	117,963,684	1,796,022	2,061,977	--	21,320,318	Majority: yes

Source: Compass Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-11 — read the filing on EDGAR.

How asset managers voted at the Compass Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 165 asset managers that disclosed a Compass Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Compass Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 117,963,684AGAINST: 1,796,022

Compass Therapeutics, Inc.’s own tally for this item (“Proposal 3: . Non-binding, Advisory Vote on the Compensation of our Named Executive Officers. The stockholders voted to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officer”): 117,963,684 for, 1,796,022 against, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 180,087,915 outstanding shares: 66% for, 1.0% against (67% of the company cast a for/against vote).

The 165 asset managers below cast 99% of the shares they voted on this item FOR (111,909,604 for, 1,131,167 against).

FOR 97%

FOR: 111,909,604 (96.9%)AGAINST: 1,131,167 (1.0%)ABSTAIN: 2,425,878 (2.1%)NOT VOTED: 274 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at Compass Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
ORBIMED ADVISORS LLC	15,219,994	0	0	For
Vivo Capital, LLC	9,545,466	0	0	For
MONTANOVA CAPITAL, LLC	9,430,768	0	0	For
Vanguard	8,258,708	5,715	4	For
Enavate Sciences GP, LLC	7,788,150	0	0	For
BVF INC/IL	7,764,842	0	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	7,534,934	0	0	For
BlackRock	5,830,572	23,246	0	For
State Street	4,847,024	2,803	0	For
RTW INVESTMENTS, LP	4,186,599	0	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	3,606,000	0	0	For
Rock Springs Capital Management LP	3,235,008	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,028,884	0	0	For
Fidelity	2,784,471	0	0	For
GREAT POINT PARTNERS LLC	0	0	2,425,446	Abstain
Logos Global Management LP	1,691,492	0	0	For
Royce	1,619,798	0	0	For
AMERIPRISE FINANCIAL INC	1,324,221	0	0	For
Blackstone Inc.	1,191,691	0	0	For
Fisher Asset Management, LLC	1,069,398	22,777	0	For
Impresa Management LLC	855,249	0	0	For
ACUTA CAPITAL PARTNERS, LLC	851,751	0	0	For
Charles Schwab	742,034	0	0	For
First Trust	730,040	889	0	For
Voya	649,585	0	0	For

Showing the 25 largest of 165 asset managers. See all 165 in the interactive database.

2. To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.8% fund support · no official result

ONE YEAR 56%1 YEAR 33%

The 159 asset managers below cast 99.8% of the shares they voted on this item FOR (196,969 for, 380 against).

FOR: 196,969 (0.2%)AGAINST: 380 (0.0%)ABSTAIN: 2,425,446 (2.1%)ONE YEAR: 64,291,832 (56.5%)1 YEAR: 37,395,504 (32.8%)1-YR: 7,764,842 (6.8%)1-YEAR: 1,691,492 (1.5%)THREE YEARS: 85,343 (0.1%)3 YEARS: 8,403 (0.0%)NOT VOTED: 274 (0.0%)1.0: 233 (0.0%)3.0: 3 (0.0%)2.0: 2 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our ” at Compass Therapeutics, Inc., 2025-2026
Asset manager	Abstain	Vote
ORBIMED ADVISORS LLC	0	1 Year
Vivo Capital, LLC	0	One Year
MONTANOVA CAPITAL, LLC	0	One Year
Vanguard	0	One Year
Enavate Sciences GP, LLC	0	1 Year
BVF INC/IL	0	1-Yr
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	One Year
BlackRock	0	1 Year
State Street	0	One Year
RTW INVESTMENTS, LP	0	One Year
DEERFIELD MANAGEMENT COMPANY, L.P.	0	1 Year
Rock Springs Capital Management LP	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
Fidelity	0	One Year
GREAT POINT PARTNERS LLC	2,425,446	Abstain
Logos Global Management LP	0	1-Year
Royce	0	One Year
AMERIPRISE FINANCIAL INC	0	One Year
Blackstone Inc.	0	One Year
Fisher Asset Management, LLC	0	One Year
ACUTA CAPITAL PARTNERS, LLC	0	1 Year
Charles Schwab	0	1 Year
First Trust	0	One Year
Voya	0	One Year
BRAIDWELL LP	0	One Year

Showing the 25 largest of 159 asset managers. See all 159 in the interactive database.

3. To elect two class III directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Richard S. Lindahl, M.B.A.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 103,453,540WITHHELD: 18,368,143

Compass Therapeutics, Inc.’s own tally for this item (“Elect Director: Richard S. Lindahl, M.B.A.”): 103,453,540 for, 18,368,143 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 180,087,915 outstanding shares: 57% for, 10% withheld (68% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (19,066,033 for, 0 against).

FOR 93%7%

FOR: 19,066,033 (92.5%)ABSTAIN: 1,534,936 (7.5%)

Largest asset managers voting on “To elect two class III directors to our Board of Directors, to serve until the 2029 annual meeting of stockhol” at Compass Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,061,207	5,743	For
State Street	3,260,496	3,879	For
Fidelity	2,665,826	0	For
BlackRock	2,243,182	0	For
Royce	1,607,024	0	For
First Trust	0	730,040	Abstain
Charles Schwab	370,944	0	For
TIAA	284,086	0	For
Voya	263,270	0	For
Equitable	213,538	49,220	For
JPMorgan	250,232	0	For
Lincoln Financial	103,168	66,607	For
ALPS ETF Trust	0	146,607	Abstain
Tema ETF Trust	138,276	0	For
AIG/SunAmerica	0	136,348	Abstain
Brighthouse	80,797	37,906	For
ProShares	0	104,388	Abstain
Prudential/PGIM	103,000	0	For
Advisor Managed Portfolios	80,439	0	For
Global X	60,545	0	For
Northern Trust	0	59,228	Abstain
Goldman Sachs	57,797	0	For
QUANTITATIVE MASTER SERIES LLC	54,492	0	For
AQR	0	49,823	Abstain
Pacific Life	47,146	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. To elect two class III directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Thomas J. Schuetz, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 102,984,184WITHHELD: 18,837,499

Compass Therapeutics, Inc.’s own tally for this item (“Elect Director: Thomas J. Schuetz, M.D., Ph.D.”): 102,984,184 for, 18,837,499 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 180,087,915 outstanding shares: 57% for, 10% withheld (68% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (18,916,921 for, 0 against).

FOR 92%8%

FOR: 18,916,921 (91.8%)ABSTAIN: 1,684,048 (8.2%)

Largest asset managers voting on “To elect two class III directors to our Board of Directors, to serve until the 2029 annual meeting of stockhol” at Compass Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,066,917	33	For
State Street	3,260,496	3,879	For
Fidelity	2,665,826	0	For
BlackRock	2,243,182	0	For
Royce	1,607,024	0	For
First Trust	0	730,040	Abstain
Charles Schwab	370,944	0	For
TIAA	284,086	0	For
Voya	0	263,270	Abstain
Equitable	262,758	0	For
JPMorgan	250,232	0	For
Lincoln Financial	103,168	66,607	For
ALPS ETF Trust	0	146,607	Abstain
Tema ETF Trust	138,276	0	For
AIG/SunAmerica	0	136,348	Abstain
Brighthouse	80,797	37,906	For
ProShares	0	104,388	Abstain
Prudential/PGIM	103,000	0	For
Advisor Managed Portfolios	80,439	0	For
Global X	60,545	0	For
Northern Trust	59,228	0	For
Goldman Sachs	57,797	0	For
QUANTITATIVE MASTER SERIES LLC	54,492	0	For
AQR	0	49,823	Abstain
Pacific Life	47,146	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

5. To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 137,896,097AGAINST: 181,037

Compass Therapeutics, Inc.’s own tally for this item (“Proposal 2: . Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company's independent registered public accounting firm for”): 137,896,097 for, 181,037 against, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 180,087,915 outstanding shares: 77% for, 0.2% against (77% of the company cast a for/against vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (20,600,965 for, 0 against).

FOR 99.9%

FOR: 20,600,965 (100.0%)ABSTAIN: 4 (0.0%)

Largest asset managers voting on “To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for the fisc” at Compass Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,066,946	4	For
State Street	3,264,375	0	For
Fidelity	2,665,826	0	For
BlackRock	2,243,182	0	For
Royce	1,607,024	0	For
First Trust	730,040	0	For
Charles Schwab	370,944	0	For
TIAA	284,086	0	For
Voya	263,270	0	For
Equitable	262,758	0	For
JPMorgan	250,232	0	For
Lincoln Financial	169,775	0	For
ALPS ETF Trust	146,607	0	For
Tema ETF Trust	138,276	0	For
AIG/SunAmerica	136,348	0	For
Brighthouse	118,703	0	For
ProShares	104,388	0	For
Prudential/PGIM	103,000	0	For
Advisor Managed Portfolios	80,439	0	For
Global X	60,545	0	For
Northern Trust	59,228	0	For
Goldman Sachs	57,797	0	For
QUANTITATIVE MASTER SERIES LLC	54,492	0	For
AQR	49,823	0	For
Pacific Life	47,146	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Largest Compass Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Compass Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 180,087,915 shares outstanding at the time of that meeting.

Top Compass Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	ORBIMED ADVISORS LLC	8.45%
2	Vivo Capital, LLC	5.30%
3	MONTANOVA CAPITAL, LLC	5.24%
4	Vanguard	4.59%
5	Enavate Sciences GP, LLC	4.32%
6	BVF INC/IL	4.31%
7	ADAGE CAPITAL PARTNERS GP, L.L.C.	4.18%
8	BlackRock	3.25%
9	State Street	2.69%
10	RTW INVESTMENTS, LP	2.32%

Reported Compass Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Compass Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	5.28%	13F
Vanguard Group	4.47%	13F
BVF PARTNERS L P/IL	4.31%	13G
Vivo Opportunity Fund Holdings, L.P.	4.00%	13G
State Street	3.72%	13F
Geode Capital	1.98%	13F
Goldman Sachs	1.11%	13F
FMR (Fidelity)	1.00%	13F
Northern Trust	0.58%	13F
Citadel Advisors	0.49%	13F

Percentages above are of 180,087,915 shares outstanding, as reported by Compass Therapeutics, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Compass Therapeutics, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Compass Therapeutics, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 165 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,088 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Compass Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-11.

Compass Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).